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Background: Hyperuricemia and associated cardio-metabolic disorders are more prevalent in African Americans
than in European Americans. We used genome-wide admixture mapping and association testing to identify loci
with ancestry effects on serum uric acid levels.
Methods: We analyzed 1,976 African Americans from Washington, D.C, including 1,322 individuals from 328 pedigrees
and 654 unrelated individuals, enrolled in the Howard University Family Study. We performed admixture mapping and
genome-wide association testing using ~800 k autosomal single-nucleotide polymorphisms (SNPs). We performed fine
mapping by dense genotyping. We assessed functionality by a combination of bioinformatic annotation, reporter gene
assays, and gel shift experiments. We also analyzed 12,641 individuals enrolled in the National Health and Nutrition
Examination Survey.
Results: We detected a genome-wide significant locus on chromosome 11p15.4 at which serum uric acid levels
increased with increasing African ancestry, independent of kidney function. Fine-mapping identified two independent
signals in the β-globin locus. The ancestral allele at SNP rs2855126, located upstream of the hemoglobin, gamma A
gene HBG1, was associated with increased serum uric acid levels and higher expression of a reporter gene relative to
the derived allele. Hyperuricemia was associated with increased risk of hypertension in 3,767 African Americans
(Odds Ratio = 2.48, p = 2.71 × 10− 19).
Conclusions: Given that increased expression of γ-globin leads to increased levels of fetal hemoglobin which
confers protection against malaria, we hypothesize that evolution in Africa of protection against malaria may have
occurred at the cost of increased serum uric acid levels, contributing to the high rates of hyperuricemia and associated
cardio-metabolic disorders observed in African Americans.
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Uric acid is the most abundant anti-oxidant in human
plasma [1]. The primary endogenous source of uric acid
is degradation of extruded nuclei from normoblasts
during erythropoiesis [2]. An elevated level of serum uric
acid, hyperuricemia, is a risk factor for gout, and is im-
plicated in both cardiovascular disease and metabolic* Correspondence: rotimic@mail.nih.gov
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(http://creativecommons.org/publicdomain/zedisease [3]. In particular, hyperuricemia is associated with
an increased risk of hypertension that occurs at serum
uric acid concentrations lower than the supersaturation
value, indicating a risk for hypertension independent of
the development of gout [4]. Heritability estimates of
serum uric acid range from 35 % to 40 % [5–7], indicating
the presence of genetic variants influencing serum uric
acid levels. A recent genome-wide association study
(GWAS) identified several loci influencing serum uric acid
levels in both European Americans and African Americans
[8]. Furthermore, meta-analysis of GWAS in individuals ofis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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the phenotypic variance in serum uric acid levels [9].
The prevalence of hyperuricemia in the US is cur-
rently ~21 % and has been increasing over the past
few decades [10]. The estimated prevalence of hyper-
uricemia is 25.7 % in African Americans, compared to
22.1 % in European Americans [10]. Compared to
European Americans, a higher prevalence in African
Americans has been observed for cardiovascular and
metabolic diseases associated with hyperuricemia such
as hypertension [11], obesity [12], and type 2 diabetes
[13]. It is unknown how much of the higher preva-
lence of hyperuricemia in African Americans is due to
genetic vs. environmental risk factors such as diet.
Here, we used joint admixture mapping and associ-
ation testing to identify genetic variants associated
with serum uric acid levels in African Americans. This
technique is designed to discover genetic variants dif-
ferentially contributing to variance in serum uric acid
levels between the West African and European ances-
tries of admixed African Americans. We then per-
formed bioinformatic annotation, luciferase reporter
gene assays, and gel shift experiments to assess associ-
ated genetic variants for functionality.Methods
Ethics statement
Ethics approval for the Howard University Family Study
was obtained from the Howard University Institutional
Review Board. Written informed consent was obtained
from each participant. All clinical investigation was con-
ducted according to the principles expressed in the
Declaration of Helsinki.Study samples
The Howard University Family Study (HUFS) is a
population-based genetic epidemiology study of African
Americans in Washington, D.C. Enrollment occurred in
two phases, the first consisting of 1,322 individuals
from 328 families and the second consisting of 654
unrelated individuals. Study participants were not ascer-
tained for any phenotype. Using the Affymetrix Genome-
Wide Human SNP Array 6.0 (Affymetrix, Santa Clara,
California) and established quality control filters [14], we
obtained genome-wide genotypes for 808,465 autosomal
single nucleotide polymorphisms (SNPs) for all 1,976
individuals.
The National Health and Nutrition Examination Survey
(NHANES) is a nationally representative, population-
based epidemiological study of health and nutritional sta-
tus (http://www.cdc.gov/nchs/nhanes/about_nhanes.htm).
This study included 2,841 Mexican Americans, 6,907 non-
Hispanic Whites, and 2,893 non-Hispanic Blacks.Local ancestry
We estimated local ancestry, i.e., 0, 1, or 2 chromosomes of
African ancestry, for 797,831 unique autosomal SNPs using
LAMPANC version 2.3 [15] and reference allele frequen-
cies for the HapMap Phase II + III CEU (Utah residents
with northern and western European ancestry) and YRI
(Yoruba in Ibadan, Nigeria) samples (http://hapmap.n
cbi.nlm.nih.gov/downloads/frequencies/2010-08_phaseII+II
I/). Genome-wide, the average proportion of African ances-
try, also known as the individual admixture proportion or
global ancestry, was 0.799.
Heritability of serum uric acid levels
The heritability of serum uric acid levels was estimated
based on 1,314 individuals in 328 pedigrees from HUFS
using SOLAR version 4.1.2 [16].
Phenotypes
Serum uric acid levels were assessed using the
COBAS INTEGRA UA2 test (Roche Diagnostics,
Indianapolis, Indiana). Serum uric acid values were
Box-Cox transformed due to non-normality. Hyperuri-
cemia was defined as serum uric acid > 7.0 mg/dL in
males and > 6.0 mg/dL in females. Serum creatinine
levels were estimated from fasting blood samples
using the COBAS INTEGRA CREJ2 test (Roche Diag-
nostics). The estimated glomerular filtration rate
(eGFR) was calculated using the Modification of Diet
in Renal Disease Study equation: eGFR = 186 × (serum
creatinine)-1.154 × age-0.203 (×0.742 if female) (×1.210 if
Black), with serum creatinine measured in mg/dL and
eGFR measured in mL/min/1.73 m2 [17].
Joint ancestry and association testing
Using R software [18], we performed joint ancestry and
association testing as described previously [19]. Briefly,
we first performed ancestry testing, also known as
admixture mapping, using linear regression of serum
uric acid level as a function of local ancestry, adjusted
for age, sex, and individual admixture proportion. Based
on autocorrelation of local ancestry, the empirical
genome-wide testing burden of admixture mapping
was 370.7, leading to a genome-wide significance level
of 0:05370:7 ¼ 1:35 10−4 . Given a significance level of
1.35 × 10− 4 and an average of 79.9 % African ancestry,
we estimated that our sample provided 80 % power to
detect a locus explaining 2.13 % of the phenotypic
variance. We performed association testing using
linear regression of serum uric acid level as a function
of genotype stratified by local ancestry and adjusted
for age, sex, and individual admixture proportion. We
combined the association results across strata using
inverse variance-weighted fixed effects meta-analysis.
Fig. 1 Admixture mapping for serum uric acid levels. Red lines indicate the genome-wide significance level. a Unadjusted and b adjusted for the
estimated glomerular filtration rate
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genome-wide testing burden of association testing was
345470.4, leading to a genome-wide significance level
of 0:05345470:4 ¼ 1:45 10−7 . We then combined the results
from admixture mapping and association testing, using
the results from admixture mapping as prior probabilities
for association testing in the Bayesian framework.Fine-mapping
Based on the 1000 Genomes sequence data for the YRI
sample [20], we identified 152 tag SNPs for the β-globin
locus that provided 90 % coverage at r2 ≥ 0.8 of SNPs
with a minor allele frequency ≥1 % and 79 % coverage of
all SNPs [21]. Of the 152 tag SNPS, primer design was
successful for 145 and genotyping was successful for
132. Genotyping was performed using the iPlex Gold
assay on the MassARRAY platform (Sequenom, Inc., San
Diego, California).Construction of expression vectors
DNA samples harboring each SNP were amplified by poly-
merase chain reaction (PCR) using the AccuPrime™ Taq
DNA Polymerase System (Life Technologies, Carlsbad,
California). Primers used to amplify DNA fragments are
shown in Additional file 1. PCR products were firstFig. 2 Joint ancestry and association testing for serum uric acid levels. Red line
for the estimated glomerular filtration ratesubcloned into the pCR®2.1-TOPO vector (Life Technolo-
gies) and modified by site-directed mutagenesis using the
QuikChange Lightning Site-Directed Mutagenesis Kit (Agi-
lent Technologies, Santa Clara, California) to generate the
other allele. To confirm sequence identity, positive
clones were fully sequenced in both directions (Euro-
fins MWG Operon, Huntsville, Alabama). For each
SNP, an allele-positive clone was subcloned into the
selected restriction enzyme-digested pGL3-Basic lucif-
erase vector (Promega, Madison, Wisconsin) using the
Quick Ligation™ kit (New England BioLabs, Ipswich,
Massachusetts) with subsequent transformation into
JM109 competent cells (Promega). All clones were
also sequence-verified (Eurofins MWG Operon).
Cell culture and luciferase activity assay
K562 (an erythroleukemic cell line persistently ex-
pressing fetal hemoglobin) and 293 T (a transformed
human embryonic kidney cell line) cells were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). K562 cells were cultured in
Roswell Park Memorial Institute (RPMI) 1640 medium
(Life Technologies). 293 T cells were cultured in Dulbec-
co’s modified Eagle’s medium (Life Technologies). All
media contained 10 % fetal bovine serum (Life Technolo-
gies) and 1 % penicillin/streptomycin (Life Technologies).s indicate the genome-wide significance level. a Unadjusted and b adjusted
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HUFS indicates the Howard University Family Study; ASW, Americans of African
Ancestry in SW USA; CEU, Utah Residents (CEPH) with Northern and Western
European ancestry; and YRI, Yoruba in Ibadan, Nigeria.
aP-value from the test of allele frequencies from the stratum of 0 African
chromosomes vs. 2 African chromosomes.
bInverse variance-weighted effect size across the three ancestry strata. For
rs2855126, the effect size corresponds to 0.357 mg/dL per allele.
cInverse variance-weighted standard error across the three ancestry strata.
dAssociation p-value for the effect size and standard error combined across
the three ancestry strata.
eP-value from Cochran’s Q test for heterogeneity in effect size across
ancestry strata.
fThe percentage of heterogeneity in effect size estimates due to
between-strata heterogeneity.
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in 24-well plates and co-transfected with 800 ng of firefly
luciferase vector constructs containing the SNP fragments
and 80 ng of TK Renilla luciferase vector (pRL-TK vector,
Promega) using Lipofectamine 2000 (Life Technologies).
Forty-eight hours after transfection, cells were har-
vested and luciferase activity was measured using the
Dual-Luciferase® Reporter Assay System (Promega)
according to the manufacturer’s protocols. Luciferase
activity was normalized using the ratio between the
firefly luciferase activity and the TK Renilla luciferase
activity.
Electrophoretic mobility shift assay (EMSA)
Non-radioactive EMSAs were performed using a LightShift
Chemiluminescent EMSA kit (Thermo Scientific, Rockford,
IL, USA) and two biotin-labeled synthetic oligonucleotides
containing either ancestral or derived alleles (Eurofins
MWG Operon). Non-biotin-labeled synthetic oligonucleo-
tides with the same sequences were used as competitors.
Nuclear extracts from K562 cells were prepared using NE-
PER nuclear and cytoplasmic extraction reagents (ThermoScientific), incubated with 20 fmol of biotin-labeled syn-
thetic oligonucleotides for 20 minutes at room temperature
and electrophoresed on 6 % Novex DNA retardation gels
(Life Technologies). In competition reactions, nuclear ex-
tracts were incubated with 4 pmol of unlabeled synthetic
oligonucleotides. Epstein-Barr nuclear antigen (EBNA)
extract and control DNA were used as a positive con-
trol. In super-shift experiments, the extracts were pre-
incubated with antibodies (Santa Cruz Biotechnology,
Dallas, TX, USA) for 60 min on ice. Chemiluminescent
signals were developed according to the manufacturer’s
instructions.
Results
Genetic mapping of serum uric acid in African Americans
The heritability of serum uric acid levels was estimated
to be 35.4 % with a standard error of 6.6 %, providing
strong evidence for an additive genetic component. We
next analyzed serum uric acid levels in 1,007 unrelated
African Americans who were at least 20 years old. The
sample comprised 414 males and 593 females with an aver-
age age of 48.3 years (standard deviation [SD] = 13.2 years)
and an average of 79.9 % African ancestry (SD = 11.6 %).
Admixture mapping yielded one genome-wide
significant peak (likelihood of odds [LOD] score = 3.20,
p = 1.24 × 10− 4) at chromosome 11p15.4 (Fig. 1a). The
1-LOD interval, or approximately the 95 % confidence
interval, extended from 4,791,111 bp to 5,665,225 bp
(GRCh37 coordinates). At this locus, serum uric acid
levels increased with increased African ancestry. This
locus explained 1.27 % of the variance in serum uric
acid levels.
Increased serum uric acid levels could reflect increased
production or decreased renal excretion. To distinguish
between these two possibilities, we performed linear re-
gression of serum uric acid as a function of local ances-
try adjusted for age, sex, and individual admixture
proportion, with an additional adjustment for eGFR. Ad-
justment for eGFR did not substantially alter the effect of
African ancestry on serum uric acid levels at 11p15.4
(1.27 % variance explained, p = 1.24 × 10− 4 without adjust-
ment compared to 1.20 % variance explained, p = 8.31 × 10
− 5 with adjustment, Fig. 1b), indicating that the genetic as-
sociation at 11p15.4 was essentially unaffected by eGFR.
Therefore, increased serum uric acid levels were more
likely due to increased production of uric acid rather
than decreased renal excretion.
To fine-map this locus, we performed association test-
ing and combined the results with the prior admixture
mapping. After adjusting for eGFR in addition to age,
sex, and individual admixture proportion, the signal re-
solved to two SNPs: rs2855126, with a posterior prob-
ability of a joint ancestry and association effect of 0.965;
and rs2855123, with a posterior probability of a joint
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SNPs map to the β-globin locus. rs2855126 is located at
5,273,147 bp, 2,060 bp upstream of the hemoglobin,
gamma A gene HBG1. rs2855123 is located at
5,277,078 bp, 1,067 bp upstream of the hemoglobin,
gamma G gene HBG2. These two SNPs are strongly cor-
related in the 1000 Genomes ASW (Americans of
African ancestry in southwest USA, r2 = 1), CEU (r2 =
0.973), and YRI (r2 = 1) samples, as well as our HUFS
data set (r2 = 0.988). At both SNPs, the derived allele is
associated with lower serum uric acid levels and is
present at lower frequencies in the YRI sample than in
the CEU sample (Table 1), consistent with the results of
admixture mapping that demonstrated increased serum
uric acid levels with increased African ancestry.
To further interrogate the β-globin locus, we performed
genotyping for 152 tag SNPs. With these additional data,
we identified one SNP, rs11036415, more strongly associ-
ated with serum uric acid levels than either rs2855126 or
rs2855123 (Fig. 3). rs11036415 is located 403 bp down-
stream of hemoglobin, beta pseudogene 1 HBBP1 and
6.9 kb upstream of the hemoglobin, delta gene HBD.
Conditioning on rs2855126 eliminated the association
at rs2855123 (p = 0.788) but not the association at rs1
1036415 (p = 0.00427). Similarly, conditioning on rs1
1036415 did not eliminate the association at rs2855126
(p = 0.00457) or rs2855123 (p = 0.00467). Therefore,
the associations at these three SNPs reflect two dis-
tinct signals.Fig. 3 Association testing for serum uric acid levels based on dense genotHyperuricemia is common in individuals with sickle cell
disease [22], raising the possibility that the variant rs334 in
the hemoglobin, beta gene HBB that leads to hemoglobin S
in sickle-cell disease was driving the association we ob-
served between the β-globin locus and serum uric acid
levels. Unfortunately, rs334 could not be genotyped using
our approach. However, based on the 1000 Genomes
Project ASW sequence data, rs334 is not correlated with
rs2855123 (r2 = 0.030), rs2855126 (r2 = 0.030), or
rs11036415 (r2 = 0.050), suggesting an effect independent of
rs334 and HBB. Similarly, the −158 C→T variant in the
HBG2 promoter (rs7482144), associated with hereditary
persistence of fetal hemoglobin [23], is not correlated with
rs2855123 (r2 = 0.020), rs2855126 (r2 = 0.020), or
rs11036415 (r2 = 0.010) in the 1000 Genomes Project ASW
sequence data.
Bioinformatic annotation
We next performed bioinformatic annotation for the top
associated SNPs at the β-globin locus. Using rs2855123,
rs2855126, and rs11036415, we queried HaploReg v2
[24] for variants with r2 ≥ 0.8 in the sequence data from
the 1000 Genomes African samples. Three SNPs
(rs2855126, rs2855125, and rs11036496) were annotated
as binding proteins based on ChIP-seq experiments
(Additional file 2). Based on the dense genotyping and
annotation, we selected rs2855125 (protein binding,
DNase I hypersensitive site, and promoter histone
marks), rs2855126 (protein binding and enhanceryping of the β-globin locus.
+ + + + + + + + + + + + + + + + + +  + + + + + + + + + 
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Fig. 5 Binding of nuclear proteins from K562 cells with SNPs rs2855126, rs11036496, and rs4348933 determined by EMSA. Lanes 1, 4, and 7: in the
absence of nuclear extract, biotin-labeled probe shows no retardation; lanes 2, 5, and 8: in the presence of nuclear extract, biotin-labeled probe shows
retardation and gel shift due to the slower migration of protein-probe complex; and lanes 3, 6, and 9: in the presence of nuclear extract and unlabeled
























































Fig. 4 Luciferase expression results from transfected K562 and 293 T cells. a Schematic illustration of luciferase reporter constructs for each
SNP. b Luciferase reporter constructs containing ancestral alleles (rs2855125-A, rs2855126-G, rs11036415-G, rs11036496-G, rs4320977-T, and
rs4348933-T) or derived alleles (rs2855125-C, rs2855126-C, rs11036415-T, rs11036496-C, rs4320977-C, and rs4348933-C) were transiently transfected into
K562 or 293 T cells. Cell lysates were analyzed for firefly and Renilla luciferase activity and the ratio of firefly/Renilla luciferase fluorescence was calculated.
Data represent the average ± one SD from three replicates, * p≤ 0.05.
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Table 2 Biochemical characterization of hyperuricemia in 2,882
NHANES non-Hispanic Blacks.
Effect Size □ P
LDH, U/L 7.88 2.06 × 10−5
BIL, mg/dL 0.0338 0.0355
RBC, 106 cells/μL 0.0529 0.0234
RDW, % 0.263 3.10 × 10−4
HCT, % 0.346 0.0471
HGB, g/dL 0.107 0.0783
MCV, fL −0.267 0.396
MCH, pg −0.121 0.340
MCHC, g/dL −0.0271 0.568
Iron, μg/dL −1.44 0.323
LDH indicates lactate dehydrogenase; BIL, total bilirubin; RBC, red blood cell
count; RDW, red cell distribution width; HCT, hematocrit; HGB, hemoglobin;
MCV, mean cell volume; MCH, mean cell hemoglobin; and MCHC, mean cell
hemoglobin concentration.
□ Effect sizes from linear regression of variable as a function of hyperuricemia
case/control status, adjusted for sex and age. Hyperuricemia was defined as
serum uric acid > 7.0 mg/dL in males or > 6.0 mg/dL in females.
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cer histone marks), and rs11036496 (protein binding,
DNase I hypersensitive site, and enhancer histone
marks), as well as rs4320977 and rs4348933 (chosen
based on the possibility that both of these variants are
associated and that the peak of association maps to
somewhere in between these two SNPs) for follow-up
functional analysis.
SNPs rs4348933 and rs11036496 are located 9.0 kb
and 4.0 kb upstream of HBG2, respectively. SNPs
rs2855125 and rs2855126 are located 2.6 kb and 2.1 kb
upstream of HBG1, respectively. SNPS rs11036415 and
rs4320977 are located 6.9 kb and 2.3 upstream of HBD,
respectively. We found no promoter regions in DNA se-
quences surrounding each of the six SNPs using Pro-
moter Inspector (Genomatix Software Inc., Ann Arbor,
MI, USA). In contrast, all six SNPs mapped to transcrip-
tion factor binding sites using SNP Inspector (Genoma-
tix Software Inc.). None of the associated SNPs are
protein-coding; rather, the associated SNPs are anno-
tated with regulatory functions more consistent with en-
hancers than promoters.rs11036496
C-allele G-allele 

























































Fig. 6 Gel supershift assay with the addition of an anti-NRF2 antibody
but not with an isotype control (IgG) identifies NRF2 as a transcription
factor binding with DNA sequences surrounding rs11036496.
NRF2 binding was not different by allele across three individual
experiments (p = 0.15).Reporter gene expression studies of intergenic SNPs in
the β-globin cluster
To determine the potential activities of the six SNPs as
enhancers or repressors of gene expression, we cloned
fragments containing the six SNPs into a firefly lucifer-
ase reporter vector (one fragment for each allele, yield-
ing 12 constructs) and co-transfected K562 or 293 T
cells with both firefly and Renilla luciferase vectors.
Expression of firefly luciferase driven by each allele-
containing DNA fragment was measured by a dual
luciferase reporter assay and normalized using Renilla
luciferase expression. SNPs rs2855126, rs11036496, and
rs4348933 had significantly greater expression levels of
firefly luciferase than pGL3-Basic-transfected cells in
both cell lines (p < 0.05, Fig. 4). Of these three SNPs,
only rs2855126 showed differential activity by allele, with







HUFS 1,006 2.90 (2.04, 4.13) 3.09 × 10−
NHANES Mexican
American
2,743 1.78 (1.32, 2.39) 1.37 × 10−
NHANES non-
Hispanic White




2,761 2.30 (1.81, 2.92) 8.46 × 10
−12
Hypertension was defined as being diagnosed by a doctor as having high
blood pressure or hypertension, taking anti-hypertensive medication, systolic
blood pressure≥ 140 mm Hg, or diastolic blood pressure≥ 90 mm Hg. The risk
of hypertension as a function of hyperuricemia was assessed using logistic
regression, adjusted for age, sex, and body mass index (and individual
admixture proportion in the HUFS).9
4
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Binding of nuclear proteins to DNA sequences harboring
rs2855126, rs11036496, and rs4348933
Gene expression can be modulated by regulatory
factor-binding sites in intronic regions [25]. To inves-
tigate the molecular mechanism underlying the tran-
scriptional activity associated with rs2855126,
rs11036496, and rs4348933, we determined whether
the sequences flanking these SNPs could serve as
protein-binding sites. EMSAs using nuclear extracts
isolated from K562 cells demonstrated gel shifts for
both alleles of all three SNPs that could be disrupted
by excess unlabeled probe, indicating strong in vitro
binding of nuclear protein to the sequences surround-
ing rs2855126, rs11036496, and rs4348933 (Fig. 5).
We further attempted to determine which transcrip-
tion factors bound to the sequences surrounding
these SNPs using MatInspector (Genomatix Software
Inc.) and RegulomeDB (http://www.regulomedb.org).
According to these two sources, the three SNPs ex-
hibited the potential capacity to bind with 13 tran-
scription factors (Additional file 3). Subsequent
analysis using a supershift assay demonstrated that
rs11036496 was located within a binding site for
NRF2 (Fig. 6), but that binding was not different by
allele (p = 0.15). No binding was detected for any of
the other 12 transcription factors.
Biochemical and clinical characterization of hyperuricemia
in nationally representative data
To better understand the biochemical and clinical nature
of increased serum uric acid levels, we analyzed bio-
chemical data in non-Hispanic Blacks enrolled in the
National Health and Nutrition Examination Survey
(NHANES). We observed significant association ofFig. 7 Global distribution of rs2855126. Blue represents the ancestral allelehyperuricemia with increased levels of lactate dehydro-
genase and total bilirubin (Table 2), which along with in-
creased serum uric acid levels are markers for increased
hemolysis. Hyperuricemia was also associated with in-
creased red blood cell count, increased red cell distribu-
tion width, and hematocrit (Table 2). In contrast,
hyperuricemia was not associated with hemoglobin, iron,
mean cell volume, mean cell hemoglobin, or mean cell
hemoglobin concentration (Table 2). Taken together,
these data suggest that hyperuricemia is associated with
increased hemolysis but not anemia, further suggesting a
compensatory mechanism by which increased hemolysis
does not lead to reduced red blood cell count. Clinically,
these results are more consistent with hereditary persist-
ence of fetal hemoglobin than β-thalassemia [23].
Hyperuricemia has also been reported to be a risk
factor for hypertension. In our HUFS data set, the
prevalence of hypertension increased from 42.4 % in
controls to 72.7 % in hyperuricemic cases. We found
that hyperuricemia increased the risk of hypertension
in HUFS, NHANES non-Hispanic Blacks, NHANES
non-Hispanic Whites, and NHANES Mexican Americans
(Table 3). Combining the HUFS and NHANES data (the es-
timates of risk from HUFS and NHANES non-Hispanic
Blacks were not different, p = 0.285), we estimated a 2.48-
fold increased risk (95 % confidence interval 2.03 to
3.02, p = 2.71 × 10− 19) of hypertension as a function of
hyperuricemia in African Americans. We estimated a
1.85-fold increased risk (95 % confidence interval 1.62
to 2.12, p = 3.64 × 10− 19) of hypertension as a function
of hyperuricemia in Mexican Americans and non-
Hispanic Whites (the estimates from these two eth-
nicities were not different, p = 0.759). The 2.48-fold
increased risk of hypertension in African Americans
was greater than the 1.85-fold increased risk in Mexi-
can Americans and non-Hispanic Whites (p = 0.017).and red represents the derived allele.
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To place our findings into an evolutionary context, we ex-
amined the global distribution of allele frequencies at
rs2855126 (http://browser.1000genomes.org). The highest
frequencies of the ancestral allele (>80 %) were observed
in West Africa and the lowest frequencies (<20 %) were
observed in Southeast Asia (Fig. 7). Globally, rs2855126 is
highly differentiated (FST = 0.165), with the highest pair-
wise value between Esan in Nigeria and Kinh in Ho Chi
Minh City, Vietnam (FST = 0.472).
Discussion
Increased levels of serum uric acid can result from
increased production and/or reduced excretion. In
African Americans, we found that the β-globin locus is
associated with serum uric acid levels, independent of
kidney function. Specifically, we demonstrated that the
ancestral allele C at rs2855126, located upstream of
HBG1, is associated with increased serum uric acid
levels and higher expression of a reporter gene relative
to the derived allele. We also found that hyperuricemia
is associated with markers of increased hemolysis, but
not anemia, and an increased risk of hypertension.
Association of the β-globin locus with serum uric acid
levels has not been reported in meta-analyses of GWAS
in individuals of European ancestry [9, 26, 27]. Epistatic
interactions have been described among genetic variants
associated with thalassemias and sickle cell traits [28].
Furthermore, looping interactions involving the locus
control region [29] and coordinated expression of the β-
globin locus with the α-globin locus on chromosome 16
[30] raise the possibility that additive models of genetic
association based on single markers may be inadequate
to capture in toto the variance of serum uric acid levels
explained by variants in hemoglobin genes.
According to the catalog of published GWAS [31], γ-
globin has been associated with disease severity in β0-thal-
assemia/HbE disease and fetal hemoglobin levels [32, 33].
Fetal hemoglobin, consisting of two copies of α-globin
and two copies of γ-globin, is protective against malaria
by slowing growth of Plasmodium falciparum in erythro-
cytes [34, 35]. Point mutations resulting in increased fetal
hemoglobin levels by increasing γ-globin gene expression
also reduce the severity of hemoglobinopathies [23, 36].
We hypothesize that the alleles associated with increased
levels of serum uric acid are associated with up-regulation
of γ-globin gene expression. The ancestral allele at
rs2855126 ranges in frequency from 88 % in the ESN
(Esan in Nigeria) sample to 19 % in the KHV (Kinh in Ho
Chi Minh City, Vietnam) sample [20], indicating a very
high level of genetic differentiation at this locus, consistent
with natural selection favoring the ancestral allele in West
Africa but favoring the derived allele in Southeast Asia. P.
falciparum accounts for most malaria in Africa whereas P.vivax accounts for most malaria in Asia and South
America and is rare in Africa [37]. Whereas P. falciparum
can infect erythrocytes of all ages, P. vivax targets reticulo-
cytes and is less lethal [37], consistent with stronger pres-
sure for the protective effect of the ancestral allele in
response to P. falciparum infection.
The malarial parasite Plasmodium falciparum requires
hypoxanthine (interconverted into uric acid by xanthine
dehydrogenase) because it cannot synthesize purines de
novo [38]. Uric acid is released when infected erythrocytes
rupture. Uric acid has potent anti-oxidant properties and
is the most abundant anti-oxidant in plasma [1, 39], but it
also can act as a pro-oxidant. As a pro-oxidant, uric acid
alters intracellular redox and activates ERK1/2 and p38
MAPK signaling pathways [40]. Consequently, uric acid
induces TNF, IL-6, IL-1β, and IL-10, which can clear the
parasite but can also damage the host [41, 42].
Five lines of evidence support the hypothesis that
rs2855126 is part of a regulatory element. From the EN-
CODE data, (1) enhancer histone marks in K562 cells
indicate a strong enhancer state, and (2) ChIP-seq data
indicate the presence in K562 cells of a binding site for
POL2A [43]. (3) RNA protection assays/reverse
transcriptase-PCR transcription analyses indicate the
presence of a major transcription start site [44]. (4)
There is evidence of cis-eQTL activity at rs2855126 for
HBG1 and HBG2 in monocytes [45]. Finally, (5) we
found allele-specific activity in reporter gene expression
in transient transfections of K562 and 293 T cells.
Gene expression levels are heritable and several diseases
have been associated with non-coding SNPs [46, 47].
Here, we demonstrated that an intergenic region in the β-
globin gene cluster acts as an enhancer. We hypothesize
that up-regulation of γ-globin leads to hemoglobin imbal-
ance. Hemoglobin associated with the red blood cell
membrane induces oxidative damage to specific cytoskel-
etal components [48], and oxidative stress plays a major
role in hemolysis [49, 50]. The degree of imbalance be-
tween α- and non-α-globin chain synthesis and the size of
the free α-chain pool are also implicated in the severity
and clinical manifestations of β-thalassemia [51].
Hyperuricemia is a risk factor for hypertension [52].
Uric acid rapidly and irreversibly inactivates nitric
oxide [53]. Cell-free hemoglobin also limits nitric
oxide bioavailability [54, 55]. Inhibition of nitric oxide
in blood vessels leads to reduced elasticity and in-
creased blood pressure [56]. Elevated serum uric acid
levels also induce activation of the renin-angiotensin
pathway, leading to vasoconstriction and acute eleva-
tion of blood pressure [57]. This acute elevation of
blood pressure is reversible by reducing serum uric
acid levels or blocking the renin-angiotensin pathway
[57]. Uric acid uptake into vascular smooth muscle
cells leads to arteriolosclerosis and impaired pressure
Shriner et al. BMC Medical Genetics  (2015) 16:103 Page 10 of 11natriuresis, leading to chronic elevation of blood pres-
sure that is uric acid-independent and sodium-
sensitive [57].
Conclusions
We discovered an association of the β-globin locus with
serum uric acid levels in admixed African Americans. At
rs2855126, the ancestral allele is associated with higher
levels of serum uric acid and higher levels of reporter
gene expression. We hypothesize that enhancer activity
associated with the ancestral allele drives higher expres-
sion of γ-globin, leading to increased levels of fetal
hemoglobin and conferring protection against malaria
independent of hemoglobin S. We also hypothesize that
higher expression of γ-globin leads to hemoglobin im-
balance, in turn leading to increased hemolysis and
higher levels of serum uric acid. Subsequently, higher
levels of serum uric acid are associated with increased
risk of hyperuricemia and hypertension.
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